AstraZeneca releases half year results
Despite the challenges – primarily as a result of the expected loss of exclusivity on some products – our underlying performance in first half of the year reflects the resilience of several of our brands and the benefits of disciplined cost management. We also made significant progress in bolstering our late-stage pipeline and on-market portfolio through external opportunities that represent a good strategic fit and add value.
Our long-term priorities for the business remain unchanged. We are driving the performance of brands that retain exclusivity, investing in markets with long-term potential, reshaping the cost base for sustainable competitiveness and remaining focused on improving the returns on our investments in innovation.
The full set of results and tables can be found here.